Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Jaguar Health Inc (JAGX)

Jaguar Health Inc (JAGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 188,509
  • Shares Outstanding, K 117,818
  • Annual Sales, $ 5,780 K
  • Annual Income, $ -38,540 K
  • 60-Month Beta 1.52
  • Price/Sales 4.38
  • Price/Cash Flow N/A
  • Price/Book 71.55
Trade JAGX with:

Options Overview

Details
  • Implied Volatility 265.22%
  • Historical Volatility 117.14%
  • IV Percentile 96%
  • IV Rank 100.00%
  • IV High 265.22% on 03/05/21
  • IV Low 217.93% on 03/01/21
  • Put/Call Vol Ratio 0.07
  • Today's Volume 1,544
  • Volume Avg (30-Day) 4,949
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 39,085
  • Open Int (30-Day) 34,694

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3200 +21.21%
on 03/04/21
3.3400 -52.10%
on 02/18/21
-1.1200 (-41.18%)
since 02/05/21
3-Month
0.3201 +399.84%
on 12/15/20
4.4700 -64.21%
on 01/08/21
+1.2580 (+367.84%)
since 12/04/20
52-Week
0.1850 +764.86%
on 11/16/20
4.4700 -64.21%
on 01/08/21
+0.9501 (+146.19%)
since 03/05/20

Most Recent Stories

More News
Jaguar Health Enters Binding Term Sheet for $5 Million Non-dilutive Financing Transaction Involving Sale of Royalty Rights Related to Future Potential Crofelemer (Mytesi) COVID-related Indication Revenue Stream

No royalty payments due for 36 months

JAGX : 1.6000 (-0.62%)
Monteverde & Associates PC Announces Proposed Class Action Settlement On Behalf Of Holders Of Jaguar Animal Health Common Stock

, /PRNewswire/ -- The following statement is being issued by Monteverde & Associates PC in regard to a proposed class action settlement.

JAGX : 1.6000 (-0.62%)
Jaguar Health Launches Website for Napo EU

Site contains links to information about post-COVID-19 'long-hauler' syndrome

JAGX : 1.6000 (-0.62%)
Jaguar Health Announces Commitment to Move Forward with Exclusive Relationship with the Planned Dragon SPAC, which is Pursuing Listing on AIM Italia and Plans to Target Napo EU

Napo EU continues to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in 'long-hauler' covid-19 recovery patients in Europe

JAGX : 1.6000 (-0.62%)
Jaguar Health Signs Memorandum of Understanding with the Lead Sponsor of the Planned Dragon SPAC Pursuing Listing on AIM Italia, Providing the Dragon SPAC with Exclusivity for a Proposed Business Combination with Napo EU

Napo EU to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in 'long-hauler' covid-19 recovery patients in Europe

JAGX : 1.6000 (-0.62%)
Noted Natural Products Industry Veteran Dr. Nigel Gericke Joins Scientific Strategy Team for Jaguar Health's Recently Launched Mental Health Entheogen Therapeutics Initiative

Team of advisors guides strategic research to discover and develop potential novel, natural psychoactive prescription medicines derived from Jaguar's library of 2,300 plants

JAGX : 1.6000 (-0.62%)
Jaguar Health's Chief of Sustainable Supply, Dr. Steven King, an Ethnobotanist, to Discuss Crofelemer Development on February 4th at 2 PM Eastern as Part of the American Botanical Council's Sustainable Herbs Program Webinar Series

Webinar Title: The Development of Crofelemer: Connecting Ethnobotany, Conservation, Biocultural Diversity, Indigenous Knowledge and Global Public Health

JAGX : 1.6000 (-0.62%)
Thinking about buying stock in Nokia, Sorrento Therapeutics, BlackBerry, Viveve Medical, or Jaguar Health?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOK, SRNE, BB, VIVE, and JAGX.

JAGX : 1.6000 (-0.62%)
SRNE : 8.88 (+0.79%)
VIVE : 2.95 (-2.32%)
BB : 9.45 (-3.96%)
NOK : 3.88 (+1.57%)
REMINDER: Jaguar Health and Sponsor of Proposed Post Pandemic Recovery Equity SPAC to Host Webcast Wednesday, January 27th at 8:30 AM Eastern Time to Provide Updates Regarding the Potential Merger of Napo EU, the Company's Anticipated Subsidiary in Italy

Webcast registration link appears below

JAGX : 1.6000 (-0.62%)
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, CA / ACCESSWIRE / January 22, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that effective December 9, 2020, the Company granted nonstatutory stock...

JAGX : 1.6000 (-0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Jaguar Health, Inc. is a natural-products pharmaceuticals company. It focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals. The company through its subsidiary Napo Pharmaceuticals Inc., focuses on developing and commercializing...

See More

Key Turning Points

3rd Resistance Point 2.1333
2nd Resistance Point 1.9267
1st Resistance Point 1.7633
Last Price 1.6000
1st Support Level 1.3933
2nd Support Level 1.1867
3rd Support Level 1.0233

See More

52-Week High 4.4700
Fibonacci 61.8% 2.8331
Fibonacci 50% 2.3275
Fibonacci 38.2% 1.8219
Last Price 1.6000
52-Week Low 0.1850

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar